REFERENCE

1.       Staskin DR, Herschorn S, Wagg A, Heesakkers J, Cardozo L, Milsom I, Chapple C, Cruz F, Stoelzel M, Schermer C, Siddiqui E, Mirabegron Integrated Database. Mirabegron integrated database: Do safety and tolerability differ by sex? Eur Urol Suppl. 2018;17(2):e1537-8–e1538. doi: 10.1016/S1569-9056(18)31908-0.

2.       Wagg A, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L. Persistence and adherence with mirabegron versus antimuscarinics in overactive bladder: retrospective analysis of a Uk General Practice Prescription Database. Eur J Obstet Gynecol Reprod Biol. 2017;211:199-200. doi: 10.1016/j.ejogrb.2017.01.028.

3.       Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, Uno S, Yamaguchi O. Lba13 Efficacy and Safety of Add-on mirabegron vs. placebo to tamsulosin in Men with overactive bladder Symptoms (Match Study). J Urol. 2018;199(4):e988.

4.       Foley S, Choudhury N, Huang M, Stari A, Nazir J, Freeman R. Quality of life in older patients with overactive bladder treated with mirabegron in routine clinical practice: secondary analysis of a pan-European non-interventional Study (BELIEVE). Eur Urol Suppl. 2018;17(2):e1554-5–e1555. doi: 10.1016/S1569-9056(18)31919-5.

5.       Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: A retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389-99. doi: 10.1016/j.eururo.2017.01.037, PMID 28196724.

6.       Pouleur AC, Anker S, Brito D, Brosteanu O, Hasenclever D, Casadei B, Edelmann F, Filippatos G, Gruson D, Ikonomidis I, L’Hummel R, Mahmod M, Neubauer S, Persu A, Gerber BL, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu JN, Van Overstraeten N, Wachter R, Balligand JL. Rationale and design of a multicentre, randomized, placebo?controlled trial of mirabegron, a Beta 3?adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta 3?left ventricular hypertrophy (Beta 3?LVH). E.S.C. Heart Fail. 2018;5(5):830-41.

7.       Babu GR, Kumar GV, Kalyani M, Roshna M, Rani PJ, Kumar PV, Ajay S. Stability-indicating simultaneous estimation of vildagliptin and mirabegron in bulk and pharmaceutical dosage form by using Uv spectroscopy. World J Pharm Pharm Sci. 2017;6(5):912-25. doi: 10.20959/wjpps20175-9086.

8.       Rezaei M, Ramazani A. RP-HPLC method development and validation for the quantitative estimation of mirabegron in extended-release tablets. J. Med. Chem Sci. 2018;1:36-40.

9.       Teijlingen Rv, Meijer J, Takusagawa S, Gelderen Mv, Beld Cv, Usui T. Development and validation of LC–MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic Study. J Chromatogr B. 2012;887-888:102-11. doi: 10.1016/j.jchromb.2012.01.018, PMID 22317789.

10.     Kalariya PD, Sharma M, Garg P, Thota JR, Ragampeta S, Talluri MVNK. Characterization of stress degradation products of mirabegron using UPLC-QTOF-MS/MS and in silico toxicity predictions of its degradation products. R.S.C. Adv. 2015;5(39):31024-38!divAbstract. doi: 10.1039/C5RA01711D.

11.     Parsha S, Ravindra Kumar Y, Ravichander M, Prakash L, Sudharani B. LC–MS/MS and NMR characterization of forced degradation products of mirabegron. J Liq Chromatogr Relat Technol. 2016;39(4):178-94. doi: 10.1080/10826076.2016.1144201.

12.     Ravisankar P, Vidya VS, Nithya PD, Babu PS. Validated UV spectrophotometric method for quantitative determination of mirabegron in bulk and pharmaceutical dosage form. Pharm Lett. 2016;8(14):96-103.

13.     Rezaei M, Ramazani A. RP-HPLC method development and validation for the quantitative estimation of mirabegron in extended-release tablets. J. Med. Chem Sci. 2018;1:36-40.

14.     Paisa GR, Rao RA. Analytical method development and validation of mirabegron by RP-HPLC method. J Pharm Res. 2017;11(6):682-5.

15.     Spandana R et al. Analytical method development and validation for the estimation of mirabegron in bulk and pharmaceutical dosage form by RP-HPLC. Indo Am J Pharm Res. 2016;6(11):6880-7.

16.     Rekulapally VK, Palavai SR, Seelam RR. A novel simultaneous stability-indicating UPLC assay method for metformin hydrochloride and canagliflozin in oral solid dosage form. Int J Adv Pharm Biotechnol;04(1):10-22. doi: 10.38111/ijapb.20180401002.

17.     Korstanje C, Suzuki M, Yuno K, Sato S, Ukai M, Schneidkraut MJ, Yan GX. Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron. J Pharmacol Toxicol Methods. 2017 Sep 1;87:74-81. doi: 10.1016/j.vascn.2017.04.008, PMID 28434969.

18.     van Gelderen M, Tretter R, Meijer J, Dorrepaal C, Gangaram-Panday S, Brooks A, Krauwinkel W, Dickinson J. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men. Int J Clin Pharmacol Ther. 2014 Aug;52(8):693-701. doi: 10.5414/CP201979, PMID 24755125.

19.     Khullar V, Cambronero J, Angulo JC, Wooning M, Blauwet MB, Dorrepaal C, Martin NE. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. B.M.C. Urol. 2013 Dec 1;13(1):45. doi: 10.1186/1471-2490-13-45, PMID 24047126.